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Aim:  
Bone loss associated with trauma, osteo-degenerative diseases and tumors has 
tremendous socioeconomic impact related to personal and occupation disability and 
health care costs. In the present climate of increasing life expectancy with an ensuing 
increase in bone-related injuries, orthopaedic surgery is undergoing a paradigm shift 
from bone-grafting to bone engineering, where a scaffold is implanted to provide 
adequate load bearing and enhance tissue regeneration. We aim to develop composite 
scaffolds for bone tissue engineering applications to replace the current gold standard 
of autografting. 
 
Methods:  
Medical grade polycaprolactone-tricalcium phosphate (mPCL/TCP) scaffolds (80/20 
wt%) were custom made using fused deposition modelling to produce 1x1.5x2 cm sized 
implants for critical-sized pig cranial implantations, empty defects were used as a 
control. Autologous bone marrow stromal cells (BMSCs) were extracted and pre-
cultured for 2 weeks, dispersed within fibrin glue and injected during scaffold 
implantation. After 2 years, microcomputed tomography and histology were used to 
assess bone regenerative capabilities of cell versus cell-free scaffolds.  
 
Results:  
Extensive bone regeneration was evident throughout the entire scaffold. Clear 
osteocytes embedded within mineralised matrix and active osteoblasts present around 
scaffold struts were observed. Cell groups performed better than cell-free scaffolds. 
 
Conclusions:  
Bone regeneration within defects which cannot heal unassisted can be achieved using 
mPCL/TCP scaffolds. This is improved by the inclusion of autogenous BMSCs. Further 
work will include the inclusion of growth factors including BMP-2, VEGF and PDGF to 
provide multifunctional scaffolds, where the three-dimensional (3D) template itself acts 
as a biomimetic, programmable and multi-drug delivery device. 
 
 
